Jefferies Group LLC set a $8.00 target price on Aratana Therapeutics Inc (NASDAQ:PETX) in a research note released on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on PETX. ValuEngine upgraded shares of Aratana Therapeutics from a sell rating to a hold rating in a research note on Tuesday, July 25th. Zacks Investment Research lowered shares of Aratana Therapeutics from a hold rating to a sell rating in a research note on Wednesday, May 10th. BidaskClub lowered shares of Aratana Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 19th. Finally, Stifel Nicolaus reduced their price objective on shares of Aratana Therapeutics from $8.00 to $7.00 and set a buy rating for the company in a research note on Wednesday, May 10th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $10.00.

Aratana Therapeutics (NASDAQ:PETX) traded down 0.15% during midday trading on Friday, hitting $6.52. 215,309 shares of the stock were exchanged. The company’s market cap is $247.48 million. Aratana Therapeutics has a 12 month low of $4.97 and a 12 month high of $10.73. The firm’s 50 day moving average price is $7.07 and its 200 day moving average price is $6.46.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.03. The firm had revenue of $5.16 million during the quarter, compared to analyst estimates of $4.50 million. Aratana Therapeutics had a negative net margin of 201.24% and a negative return on equity of 45.98%. Aratana Therapeutics’s revenue was down 86.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.61 EPS. On average, equities research analysts forecast that Aratana Therapeutics will post ($1.03) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aratana Therapeutics Inc (NASDAQ:PETX) Given a $8.00 Price Target at Jefferies Group LLC” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/05/aratana-therapeutics-inc-nasdaqpetx-given-a-8-00-price-target-at-jefferies-group-llc.html.

A number of hedge funds have recently added to or reduced their stakes in the company. Tocqueville Asset Management L.P. increased its stake in Aratana Therapeutics by 3.3% in the second quarter. Tocqueville Asset Management L.P. now owns 258,150 shares of the biopharmaceutical company’s stock valued at $1,866,000 after buying an additional 8,150 shares in the last quarter. Cadence Capital Management LLC increased its stake in Aratana Therapeutics by 25.3% in the second quarter. Cadence Capital Management LLC now owns 165,359 shares of the biopharmaceutical company’s stock valued at $1,196,000 after buying an additional 33,433 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Aratana Therapeutics by 8.9% in the second quarter. Bank of New York Mellon Corp now owns 137,102 shares of the biopharmaceutical company’s stock valued at $992,000 after buying an additional 11,229 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in Aratana Therapeutics during the second quarter valued at $210,000. Finally, Rhumbline Advisers increased its stake in Aratana Therapeutics by 16.4% in the second quarter. Rhumbline Advisers now owns 48,214 shares of the biopharmaceutical company’s stock valued at $349,000 after buying an additional 6,800 shares in the last quarter. 67.55% of the stock is currently owned by institutional investors.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.